We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Removal of a p53 Inhibitor Causes Cancer Cell Death

By LabMedica International staff writers
Posted on 06 Jul 2009
Print article
Cancer researchers employing a novel technique to study the p53 tumor suppressor gene in normal rather than cancerous tissues have identified Trim24 as a p53 inhibitor that may be susceptible to drug treatment.

Tripartite motif-containing 24 (Trim24) also known as transcriptional intermediary factor 1-alpha (TIF1-alpha) is a protein, which in humans is encoded by the Trim24 gene. The protein encoded by this gene mediates transcriptional control by interaction with the activation function-2 (AF-2) region of several nuclear receptors, including the estrogen, retinoic acid, and vitamin D3 receptors. The protein localizes to nuclear bodies and is thought to associate with chromatin and heterochromatin-associated factors.

Investigators at the University of Texas M. D. Anderson Cancer Center (Houston, USA) created a mouse and stem cell model by knock-in (KI) genetic engineering. The new line of mice had a tandem-affinity-purification (TAP) epitope linked to p53. Mass spectrometry of TAP-purified p53-complexes from embryonic stem cells revealed the presence of Trim24, a previously unknown partner of p53.

Results from additional experiments published in the June 25, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) showed that expression of p53 activity was inversely proportional to the levels of Trim24. Trim24 marked the p53 protein with ubiquitin for proteosomal destruction. Complete removal of Trim24 in human breast cancer cells caused p53-dependent, spontaneous apoptosis.

"We wanted to purify p53 from normal cells to better understand the mechanisms that regulate it," said senior author Dr. Michelle Barton, professor of biochemistry and molecular biology at University of Texas M. D. Anderson Cancer Center. "Targeting Trim24 may offer a therapeutic approach to restoring p53 and killing tumor cells."

Related Links:
University of Texas M. D. Anderson Cancer Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The utilization of liquid biopsies in cancer research is a rapidly developing field (Photo courtesy of Lightspring/Shutterstock)

Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis

B-cell lymphoma is the predominant form of cancer affecting the lymphatic system, with about 30% of patients with aggressive forms of this disease experiencing relapse. Currently, the disease’s risk assessment... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.